The only thing I see is that they want Xtoll, but their exprience and expertise seems to be with chest and heart not anti-inflammatory conditions. This was why Novo wanted Xtoll as that is what they specialse in.
Other reason could be to offset risk, pickup access to easy money, rope in a few more aussies for the risk. I imagine investors a very nervous in US, so might be hard to get funds.
Think CBIO looses 37% in the deal, and they get a chance that they get a drug that might or might not be a winner in about 3 to 5 years.
- Forums
- ASX - By Stock
- asx announcement
The only thing I see is that they want Xtoll, but their...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CBZ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online